Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

Evidence-Based Research

Clinical Trials Database

Track peptide clinical trials from early-phase research through FDA approval. Real data from ClinicalTrials.gov and published peer-reviewed literature.

14Trials Tracked

10Completed

3FDA Approved

Semaglutide

SELECT Trial

Phase 3

NCT03574597

Cardiovascular outcomes in obesity

Sponsor: Novo Nordisk

Completed

Key Result

20% reduction in major adverse cardiovascular events (MACE)

Tirzepatide

SURMOUNT-1

Phase 3

NCT04184622

Weight management in obesity

Sponsor: Eli Lilly

Completed

Key Result

Up to 22.5% body weight reduction at 72 weeks

Retatrutide

Phase 2 Obesity Trial

Phase 2

NCT04881760

Obesity treatment

Sponsor: Eli Lilly

Completed

Key Result

Up to 24% body weight loss at 48 weeks

BPC-157

Multiple Preclinical Studies

Preclinical

Tissue repair and healing

Sponsor: Various academic centers

Ongoing

Key Result

Demonstrated tendon, ligament, and gut healing in animal models

Tesamorelin

REALIZE Trial

Phase 3

NCT01263717

HIV-associated lipodystrophy

Sponsor: Theratechnologies

FDA Approved

Key Result

Significant reduction in visceral adipose tissue; FDA approved as Egrifta

Bremelanotide (PT-141)

RECONNECT

Phase 3

NCT02333071

Hypoactive sexual desire disorder in women

Sponsor: Palatin Technologies

FDA Approved

Key Result

Statistically significant improvement in sexual desire; FDA approved as Vyleesi

Sermorelin

Growth Hormone Deficiency Trials

Phase 3

Growth hormone deficiency

Sponsor: EMD Serono

FDA Approved

Key Result

Effective stimulation of endogenous GH secretion; FDA approved for pediatric GHD

CJC-1295 + Ipamorelin

GH Optimization Study

Phase 2

Growth hormone optimization

Sponsor: ConjuChem Biotechnologies

Investigational

Key Result

Sustained GH elevation with favorable safety profile in early trials

Thymosin Alpha 1

Immune Modulation Trials

Phase 2/3

Immune modulation in cancer and hepatitis

Sponsor: SciClone Pharmaceuticals

Completed

Key Result

Enhanced immune response; approved in 35+ countries for hepatitis B

AOD-9604

Anti-Obesity Phase 2b

Phase 2

Anti-obesity drug fragment

Sponsor: Metabolic Pharmaceuticals

Completed

Key Result

Demonstrated fat reduction without affecting IGF-1 or glucose levels

Epithalon

Telomerase Activation Research

Preclinical

Anti-aging and telomerase activation

Sponsor: Khavinson Institute of Gerontology

Research Phase

Key Result

Increased telomerase activity and telomere elongation in cell studies

GHK-Cu

Wound Healing Studies

Phase 1

Wound healing and skin repair

Sponsor: Multiple research institutions

Ongoing

Key Result

Accelerated wound healing and collagen synthesis in clinical observations

Semaglutide

FLOW Trial

Phase 3

NCT03819153

Chronic kidney disease in type 2 diabetes

Sponsor: Novo Nordisk

Completed

Key Result

24% reduction in kidney disease progression; trial stopped early for efficacy

Tirzepatide

SURPASS-1

Phase 3

NCT03954834

Type 2 diabetes mellitus

Sponsor: Eli Lilly

Completed

Key Result

HbA1c reduction up to 2.07% and superior glycemic control vs placebo

Data sourced from ClinicalTrials.gov and published peer-reviewed literature. Trial results are simplified summaries and may not reflect full study outcomes. Always consult primary sources for complete data.